Citigroup Inc Argenx Se Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Argenx Se stock. As of the latest transaction made, Citigroup Inc holds 6,531 shares of ARGX stock, worth $3.68 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

6,531

Previous 7,194 9.22%

Holding current value

$3.68 Million

Previous $3.09 Million 14.52%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$434.22 - $551.9 $287,887 - $365,909	-663 Reduced 9.22%	6,531 $3.54 Million
Q2 2024 Aug 12, 2024	BUY	$356.01 - $451.55 $770,049 - $976,702	2,163 Added 42.99%	7,194 $3.09 Million
Q1 2024 May 10, 2024	BUY	$356.95 - $413.29 $121,719 - $140,931	341 Added 7.27%	5,031 $1.98 Million
Q4 2023 Feb 09, 2024	SELL	$338.91 - $506.01 $6.29 Million - $9.4 Million	-18,567 Reduced 79.83%	4,690 $1.78 Million
Q3 2023 Nov 09, 2023	BUY	$369.35 - $548.43 $7.54 Million - $11.2 Million	20,427 Added 721.8%	23,257 $11.4 Million
Q2 2023 Aug 10, 2023	BUY	$360.14 - $422.58 $473,944 - $556,115	1,316 Added 86.92%	2,830 $1.1 Million
Q1 2023 May 11, 2023	BUY	$334.23 - $403.65 $93,918 - $113,425	281 Added 22.79%	1,514 $564,000
Q4 2022 Feb 09, 2023	SELL	$342.17 - $402.31 $85,200 - $100,175	-249 Reduced 16.8%	1,233 $467,000
Q3 2022 Nov 10, 2022	BUY	$343.2 - $395.75 $54,568 - $62,924	159 Added 12.02%	1,482 $522,000
Q2 2022 Aug 10, 2022	SELL	$269.58 - $378.88 $44,750 - $62,894	-166 Reduced 11.15%	1,323 $502,000
Q1 2022 May 12, 2022	BUY	$254.45 - $351.06 $37,913 - $52,307	149 Added 11.12%	1,489 $470,000
Q4 2021 Feb 10, 2022	SELL	$272.01 - $353.03 $154,229 - $200,168	-567 Reduced 29.73%	1,340 $469,000
Q3 2021 Nov 10, 2021	BUY	$295.0 - $350.58 $562,565 - $668,556	1,907 New	1,907 $576,000

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account